Marina Pasca di Magliano

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2218682/marina-pasca-di-magliano-publications-by-year.pdf
Version: 2024-04-28

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81 papers	6,578 citations	34 h-index	81 g-index
98 ext. papers	7,946 ext. citations	10.2 avg, IF	5.74 L-index

#	Paper	IF	Citations
81	Immune sensing of microbial metabolites: Action at the tumor.. *Immunity*, **2022**, 55, 192-194	32.3	0
80	Kras induces changes in chromatin territories that differentially impact early nuclear reprogramming in pancreatic cells. *Genome Biology*, **2021**, 22, 289	18.3	1
79	Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. *Life Science Alliance*, **2021**, 4,	5.8	7
78	Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. *Oncogene*, **2021**, 40, 3118-3135	9.2	5
77	Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-B-Mediated Production of CXCL1. *Cancer Research*, **2021**, 81, 4305-4318	10.1	6
76	The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**, 11, 349-369	7.9	7
75	ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. *Genes and Development*, **2021**, 35, 218-233	12.6	8
74	Immunotherapy for pancreatic ductal adenocarcinoma. *Journal of Surgical Oncology*, **2021**, 123, 751-759	2.8	5
73	Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. *Frontiers in Oncology*, **2021**, 11, 682217	5.3	7
72	Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**, 12, 1531-1542	7.9	2
71	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. *Cancer Cell*, **2021**, 39, 1227-1244.e20	24.3	32
70	New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. *Gastroenterology*, **2021**, 161, 785-791	13.3	1
69	KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Non-Canonical Activin Pathway. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**,	7.9	3
68	Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. *Clinical Cancer Research*, **2021**, 27, 2023-2037	12.9	54
67	Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. *American Journal of Pathology*, **2020**, 190, 1735-1751	5.8	10
66	Chemotherapy and Tumor Evolution Shape Pancreatic Cancer Recurrence after Resection. *Cancer Discovery*, **2020**, 10, 762-764	24.4	8
65	Context-Dependent Immune Responses Explain Pancreatic Cancer Immunoresistance. *Cancer Cell*, **2020**, 37, 261-263	24.3	3

64	Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition. *Scientific Reports*, **2020**, 10, 11133	4.9	5
63	Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis. *Cancer Discovery*, **2020**, 10, 422-439	24.4	100
62	Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. *Gastroenterology*, **2020**, 158, 1417-1432.e11	13.3	22
61	Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma. *Cellular and Molecular Gastroenterology and Hepatology*, **2020**, 10, 581-599	7.9	25
60	Pancreatic Fibroblast Heterogeneity: From Development to Cancer. *Cells*, **2020**, 9,	7.9	10
59	Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. *Cancer Research*, **2020**, 80, 3070-3071	10.1	4
58	Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. *Nature Cancer*, **2020**, 1, 1097-1112	15.4	52
57	Myeloid Cell-Derived HB-EGF Drives Tissue Recovery After Pancreatitis. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 8, 173-192	7.9	11
56	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. *Cancer Research*, **2019**, 79, 3940-3951	10.1	89
55	ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis. *Genes and Development*, **2019**, 33, 641-655	12.6	11
54	Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. *Gastroenterology*, **2019**, 156, 2073-2084	13.3	27
53	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. *Annals of Surgical Oncology*, **2019**, 26, 2821-2830	3.1	8
52	An Organoid/Immune Cell Co-Culture as a Predictive Model for the Treatment of Pancreatic Cancer. *FASEB Journal*, **2019**, 33, 869.20	0.9	1
51	Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. *Cell Metabolism*, **2019**, 29, 1390-1399.e6	24.6	164
50	Epithelial-Stromal Interactions in Pancreatic Cancer. *Annual Review of Physiology*, **2019**, 81, 211-233	23.1	18
49	Pancreatic HIF2α Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. *Cellular and Molecular Gastroenterology and Hepatology*, **2018**, 5, 169-185.e2	7.9	7
48	Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. *Neoplasia*, **2018**, 20, 152-164	6.4	11
47	Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. *American Journal of Physiology - Renal Physiology*, **2018**, 315, G27-G35	5.1	14

46	Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. *JCI Insight*, **2018**, 3,	9.9	19
45	Spatial and phenotypic immune profiling of metastatic colon cancer. *JCI Insight*, **2018**, 3,	9.9	40
44	Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. *Journal of Surgical Research*, **2018**, 232, 570-577	2.5	10
43	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. *Gut*, **2017**, 66, 124-136	19.2	178
42	Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma. *Journal of Investigative Dermatology*, **2017**, 137, 1740-1748	4.3	78
41	Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis. *Cellular and Molecular Gastroenterology and Hepatology*, **2017**, 3, 99-118	7.9	31
40	Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. *ELife*, **2017**, 6,	8.9	28
39	Early pancreatic islet fate and maturation is controlled through RBP-J *Scientific Reports*, **2016**, 6, 26874	4.9	4
38	Fbxw7 Deletion Accelerates Kras-Driven Pancreatic Tumorigenesis via Yap Accumulation. *Neoplasia*, **2016**, 18, 666-673	6.4	25
37	Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages. *Neoplasia*, **2016**, 18, 142-51	6.4	69
36	Invasive mouse gastric adenocarcinomas arising from Lgr5+ stem cells are dependent on crosstalk between the Hedgehog/GLI2 and mTOR pathways. *Oncotarget*, **2016**, 7, 10255-70	3.3	22
35	Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. *Oncotarget*, **2016**, 7, 6916-32	3.3	79
34	GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. *Cancer Discovery*, **2016**, 6, 886-99	24.4	114
33	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. *Cancer Immunology Research*, **2016**, 4, 520-30	12.5	57
32	CD44 regulates pancreatic cancer invasion through MT1-MMP. *Molecular Cancer Research*, **2015**, 13, 9-15	6.6	62
31	Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. *Carcinogenesis*, **2015**, 36, 730-8	4.6	25
30	ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis. *Genes and Development* , **2015**, 29, 171-83	12.6	48
29	CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. *Cancer Immunology Research*, **2014**, 2, 423-35	12.5	57

28	The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. *Journal of Biological Chemistry*, **2014**, 289, 27727-43	5.4	31
27	Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis. *BMC Cancer*, **2014**, 14, 862	4.8	25
26	Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. *Frontiers in Physiology*, **2014**, 5, 464	4.6	17
25	Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling. *Cell Reports*, **2014**, 9, 484-94	10.6	71
24	Immune cells in pancreatic cancer: Joining the dark side. *OncoImmunology*, **2014**, 3, e29125	7.2	5
23	MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. *Gastroenterology*, **2014**, 146, 822-834.e7	13.3	71
22	Roles for KRAS in pancreatic tumor development and progression. *Gastroenterology*, **2013**, 144, 1220-9	13.3	261
21	Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. *Cancer Research*, **2013**, 73, 6359-74	10.1	163
20	Kras as a key oncogene and therapeutic target in pancreatic cancer. *Frontiers in Physiology*, **2013**, 4, 407	4.6	92
19	Deciphering the role of stroma in pancreatic cancer. *Current Opinion in Gastroenterology*, **2013**, 29, 537-43	3	93
18	Canonical wnt signaling is required for pancreatic carcinogenesis. *Cancer Research*, **2013**, 73, 4909-22	10.1	139
17	Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. *Journal of Biological Chemistry*, **2013**, 288, 11786-94	5.4	81
16	Mouse Models of Pancreatic Ductal Adenocarcinoma **2013**, 145-170		1
15	Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. *PLoS ONE*, **2012**, 7, e49707	3.7	117
14	Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. *Journal of Clinical Investigation*, **2012**, 122, 639-53	15.9	474
13	c-Met is a marker of pancreatic cancer stem cells and therapeutic target. *Gastroenterology*, **2011**, 141, 2218-2227.e5	13.3	277
12	Pancreatic cancer and hedgehog pathway signaling: new insights. *Pancreatology*, **2010**, 10, 151-7	3.8	20
11	New frontiers in pancreatic cancer research. *Surgical Oncology Clinics of North America*, **2010**, 19, 431-51	2.7	2

10	Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. *Immunity*, **2009**, 30, 508-20	32.3	146
9	Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. *PLoS ONE*, **2007**, 2, e1155	3.7	182
8	A small-molecule antagonist of the hedgehog signaling pathway. *ChemBioChem*, **2007**, 8, 1916-9	3.8	67
7	Hedgehog/Ras interactions regulate early stages of pancreatic cancer. *Genes and Development*, **2006**, 20, 3161-73	12.6	246
6	Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature*, **2003**, 425, 851-6	50.4	1280
5	Hedgehog signalling in cancer formation and maintenance. *Nature Reviews Cancer*, **2003**, 3, 903-11	31.3	705
4	The thyroid transcription factor 2 (TTF-2) is a promoter-specific DNA-binding independent transcriptional repressor. *Biochemical and Biophysical Research Communications*, **2000**, 275, 203-8	3.4	46
3	GOT1 Inhibition Primes Pancreatic Cancer for Ferroptosis through the Autophagic Release of Labile Iron		2
2	The Pancreatic Tumor Microenvironment Compensates for Loss of GOT2		3
1	Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer		2